Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer

NCT03501979 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT03501979
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03501979 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 2
Overall status
Terminated
Start date
February 20, 2019
Completion date
June 22, 2021
Enrollment
17 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

leptomeningeal disease, metastatic breast cancer